[ascct] Join Us for ASCCT webinar: The GARD assay for skin and respiratory sensitisation

  • From: Kristie Sullivan <KSullivan@xxxxxxxx>
  • To: "ascct@xxxxxxxxxxxxx" <ascct@xxxxxxxxxxxxx>
  • Date: Wed, 29 Jul 2015 11:53:30 -0400

There are still a few slots left for the upcoming webinar, which is one week
from today. Register now!




ASCCT webinar: The GARD assay for skin and respiratory sensitisation

Join us for a webinar on Aug 05, 2015 at 11:00 AM EDT.

Register now!

https://attendee.gotowebinar.com/register/842516545615671297

Andy Forreryd, Lund University, will describe the Genomic Allergen Rapid
Detection (GARD) assay.

In order to reduce exposure to sensitizing compounds, it is of high importance
to identify possible chemical allergens before they reach the consumer market
or working environments. Therefore, a significant effort is currently invested
in the development of predictive assays for proactive identification of such
compounds.

We have developed a cell based testing strategy for assessment of both skin and
respiratory sensitizers. The assay was initially designed for the risk
assessment of skin sensitizing compounds. A panel of reference compounds
comprising skin sensitizing chemicals (N=20) and controls (N=20) were used for
stimulation of cells. Complete transcriptomes of cells were analyzed using
microarrays, and a genomic biomarker signature was identified using one-way
ANOVA p-value filtering, and further optimized using an in-house developed
wrapper algorithm. The applicability domain of GARD was later broadened to
cover prediction of respiratory sensitizers, using a panel of reference
compounds comprising respiratory sensitizers (n=10) and controls (n=22), with a
similar methodology as described for skin sensitizers.

Performances of the biomarker signatures were validated using external test
sets. The biomarker signatures were challenged with either 37 chemicals (skin
sensitization), or 25 chemicals (respiratory sensitization). Accuracy,
sensitivity and specificity were estimated to 89%, 92% and 83% for skin
sensitization, and 84%, 67% and 89% for respiratory sensitization, respectively.

The transcriptome-wide profiling used during the construction of the assay also
provides the possibility to further broaden the applicability domain of GARD to
cover also additional endpoints or relative potency. Analyzing the complete
transcriptome of cells also provides the benefit of being able to perform
mechanistic studies in order to elucidate molecular pathways that drives the
pathogenesis of allergic diseases.

After registering, you will receive a confirmation email containing information
about joining the webinar.

View System
Requirements<http://support.citrixonline.com/s/G2W/Help/SystemRequirements>






Other related posts: